Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

UK Medtech Ponders Future As New Government Gets Up To Speed

Executive Summary

Post-Brexit concerns abound for UK medtech companies who are hoping that a renewed government focus on the life sciences industry will provide the support and benefits it needs amid the uncertainties brought on by the UK vote to leave the European Union.

You may also be interested in...



Brexit Reflections For UK IVDs: Harmonized Regulation, Staff Issues Key

The UK in vitro diagnostics industry has been working on two initiatives that set out its views on how to secure a stable and competitive future for the national industry in the months following the country's vote to leave the EU.

UK Medtech Presses For Federation Structure In Post-Brexit Environment

A national federation of medtech associations is being proposed by parts of the UK industry, which often feels muscled out of the debate by pharma for big issues like handling the country's exit from the EU. The argument is that a less fragmented sector voice would have more influence on government decisions.

George Freeman Departure Leaves UK Life Sciences Holding Its Breath

Theresa May has re-structured the Department of Health ministerial team as part of her wide-ranging reshuffle and in so doing moved life sciences minister George Freeman over to chair the prime minister’s policy board. The British biopharma community says it hopes he will be replaced – and soon.

Topics

Latest News
See All
UsernamePublicRestriction

Register

MT103686

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel